EVs help cancer cells resist death by modifying BCL2 protein expression, communicating factors to help neighboring cancer cells adapt, discarding chemotherapy agents such as cisplatin from the cell, and acting as decoys to monoclonal antibodies such as trastuzumab[29-33]. This evidence concerns the gene BCL2 and cancer.